Izvorni znanstveni članak

Prognostic significance of Matrix Metalloproteinases 2 and 9 in Endometrial Cancer

Mario Puljiz ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Gynecologic Oncology, Zagreb, Croatia
Zeljko Puljiz ; University of Split, Split University Hospital Centre, Department of Gastroenterology, Split, Croatia
Tiha Vucemilo ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Transfusion Medicine, Zagreb, Croatia
Snjezana Ramic ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Clinical Pathology, Zagreb, Croatia
Fabijan Knezevic ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Clinical Pathology, Zagreb, Croatia
Branimir Culo ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Radiology, Zagreb, Croatia
Ilija Alvir ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Gynecologic Oncology, Zagreb, Croatia
Darko Tomica ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Gynecologic Oncology, Zagreb, Croatia
Damir Danolic ; University of Zagreb, »Sestre Milosrdnice« University Hospital Centre, University Hospital for Tumors, Department of Gynecologic Oncology, Zagreb, Croatia

Sažetak

We investigated the prognostic significance of matrix metalloproteinases 2 (MMP 2) and 9 (MMP 9) in endometrial cancer (EC). The expression of MMP 2 and MMP 9 was analyzed immunohistochemically in 73 primary EC patients. In most cases, the gelatinases were predominantly localized to epithelial cell of tumor origin. In univariate analysis histological type, tumor grade, FIGO (1988) surgical stage and high stromal MMP 2 expression were identified as a significant determinant for EC recurrence, while epithelial MMP 2 expression and epithelial and stromal MMP 9 expression were not. Multivariate analysis revealed a subgroup of patient age ³63.6 years with endometrioid adenocarcinoma and
papillary serous carcinoma, all FIGO (2009) stage I disease where strong staining of stromal MMP 2 increase risk of EC recurrence (p=0.037).

Ključne riječi

matrix metalloproteinase 2; matrix metalloproteinase 9; endometrial cancer; recurrence

Hrčak ID:

94957

URI

https://hrcak.srce.hr/94957

Datum izdavanja:

27.12.2012.

Posjeta: 1.331 *